Browse: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 3 |
Novartis Corporate Intellectual Property patentsThe following is a sampling of recent Novartis Corporate Intellectual Property patent applications (USPTO Patent Application #, Patent Title) sorted by month.
June 2009 - Novartis Corporate Intellectual Property patents
20090162132 - Applicator unit
20090162433 - Method of treatment
20090163523 - Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
20090163551 - Compositions and methods for treating diseases
20090156556 - Aminopropanol derivatives
20090156585 - Organic compounds
20090156588 - 3,4-dihydro-benzo[e][1,3]oxazin-2-ones
20090156602 - Organic compounds
20090156615 - Organic compounds
20090148522 - Heated roller compaction process for making pharmaceutical compositions
20090149469 - Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors
20090149543 - Solid pharmaceutical compositions comprising lumiracoxib
20090143340 - Pyrocatechin derivatives
20090143469 - Salts of nateglinide
20090143479 - Pharmaceutical compositions comprising terbinafine
20090143597 - Ionic liquids based on imidazolium salts incorporating a nitrile functionality
May 2009 - Novartis Corporate Intellectual Property patents
20090136484 - Novel antibody molecules and nucleic acids
20090136965 - Use of antibody-ligand binding to characterise diseases
20090136970 - Nogo receptor homologues and their use
20090137462 - Pharmaceutical composition comprising cyclic somatostatin analogues
20090137552 - Organic compound
20090137566 - Substituted piperdines as renin inhibitors
20090137804 - Compounds and compositions as protein kinase inhibitors
20090137805 - N-phenyl-2-pyrimidine-amine derivatives
20090131404 - Combinations
20090131408 - Organic compounds
20090131436 - Pyrimidine derivatives
20090131437 - Disubstituted ureas as kinase inhibitors
20090131450 - Use of pkc inhibitors in diabetic complications
20090131457 - Pyrazolo [3,4-d] pyrimidine derivatives useful to treat respiratory disorders
20090131477 - New use of iloperidone
20090131528 - Salt
20090123424 - Methods of protein purification and recovery
20090123566 - Use of a phosphate adsorbent to combat vascular diseases
20090117181 - Tablet comprising fluvastatin and carmellose calcium
20090118160 - Heterocyclic compounds and methods of use
20090118273 - Compounds and compositions as protein kinase inhibitors
20090118277 - 3 unsubstituted n-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as kinase inhibitors
April 2009 - Novartis Corporate Intellectual Property patents
20090110734 - Quaternised ammonium cyclodextrin compounds
20090111839 - Process for preparing amorphous rosuvastatin calcium of impurities
20090104149 - Compositions for hcv treatment
20090104149 - Compositions for hcv treatment
20090104149 - Compositions for hcv treatment
20090104263 - 5-ht4 partial agonist pharmaceutical compositions
20090104263 - 5-ht4 partial agonist pharmaceutical compositions
20090104263 - 5-ht4 partial agonist pharmaceutical compositions
20090105285 - Pharmaceutical combinations comprising a mtor inhibitor and a raf kinase inhibitor
20090105285 - Pharmaceutical combinations comprising a mtor inhibitor and a raf kinase inhibitor
20090105285 - Pharmaceutical combinations comprising a mtor inhibitor and a raf kinase inhibitor
20090105322 - Pharmaceutical composition comprising valsartan
20090105322 - Pharmaceutical composition comprising valsartan
20090105322 - Pharmaceutical composition comprising valsartan
20090098137 - Combinations of therapeutic agents for treating cancer
20090099103 - Combinations of therapeutic agents for treating cancer
20090099241 - Pharmaceutical composition containing antihypertensive agents
20090088373 - Use of compositions to enhance innate immune response
20090088373 - Use of compositions to enhance innate immune response
20090088479 - Salt of aliskiren with sulfuric acid
20090088479 - Salt of aliskiren with sulfuric acid
March 2009 - Novartis Corporate Intellectual Property patents
20090081732 - Antibodies to human il-1beta
20090081741 - Single colonies of myxobacteria cells
20090075972 - Use of midostaurin for treating gastrointestinal stromal tumors
20090076062 - Organic compounds
20090069225 - Somatostatin analogues
20090069294 - Organic compounds
20090069315 - Use of pyrazolo(1,5a)pyrimidin-7-yl amine derivatives in the treatment of neurological disorders
20090069341 - Inhibitors of hsp90
20090069394 - Cancer treatment with epothilones
20090060848 - Pharmaceutical composition which reduces or eliminates drug abuse potential
20090060899 - Composition of organic compounds
20090062301 - Pharmaceutical combination composition comprising at least one pkc inhibitor and at least one ja k3 kinase inhibitor for treating autoimmune disorders
20090062395 - Renin inhibitors for the treatment of hypertension
February 2009 - Novartis Corporate Intellectual Property patents
20090053195 - Biomarkers for acute graft rejection
20090054404 - Use of r-10-hydroxy-10,11-dihydro-carbamazepine in neuropathic pain
20090054512 - Use of organic compounds
20090054628 - Method and system for in vitro protein folding
20090054653 - Enantioselektive preparation of quinoline derivative
20090048157 - Use of organic compounds
20090048230 - Compounds and compositions useful as cathepsin s inhibitors
20090048266 - Effects of inhibitors of fgfr3 on gene transcription
20090048281 - Organic compounds
20090048344 - Pharmaceutical composition comprising 5-methyl-2-2' (chloro-6'-fluoroanilino phe nylacetic acid
20090041675 - Organic compounds
20090041715 - Epothilone combinations
20090041775 - Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract
20090043379 - Drug delivery systems for the prevention and treatment of vascular diseases
20090036352 - Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof
20090036423 - Immunosuppresant compounds and compositions
20090036432 - Combinations of at1-antagonists, amiloride or triamterine, and a diuretic
20090036507 - Bis (cyanophenyl) methyl-triazole for use in prevention of breast cancer
January 2009 - Novartis Corporate Intellectual Property patents
20090029910 - Combinations of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes
20090022730 - Methods and compositions for assessing acute rejection
20090023754 - Modified release famciclovir pharmaceutical compositions
20090023768 - Rapamycin derivatives for treating neuroblastoma
20090023805 - Method of administration
20090017015 - Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders
20090018109 - Combinations of steroids and methylxanthine compounds
20090018127 - Ergoline derivatives
20090018325 - Process for preparing l-nucleic acid derivatives and intermediates thereof
20090012066 - Method of use of deacetylase inhibitors
20090012105 - Combination of mtor inhibitor and antipolate compound
20090012298 - Process for the preparation of rapamycin derivatives
20090004283 - Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers
20090005361 - Combination of organic compounds
20090005419 - Organic compounds
October 2008 - Novartis Corporate Intellectual Property patents
20080261864 - Combination of nateglinide or repaglinide with at least one further antidiabetic compound
20080261958 - Combination of organic compounds
20080262014 - Use of camptothecin derivatives for the treatment of proliferative diseases in a fixed dosing regimen
20080262021 - 1h-imidazoquinoline derivatives as prote in kinase inhibitors
20080262050 - Organic compounds
20080262059 - Methods of treatment and pharmaceutical composition
20080262246 - 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutr an -2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors
20080262254 - Sphingolipids
20080253988 - Pyrrolo [1,2-d] [1,2-4] triazine as inhibitors of c-jun n terminal kinases (jnk) and p-38 kinases
20080254089 - Pharmaceutical products comprising bisphosphonates
20080254113 - Microemulsion formulations comprising particular substance p antagonists
20080254116 - Delta and epsilon crystal forms of imatinib mesylate
20080255029 - Neuroendocrine tumor treatment
20080255048 - Pharmaceutical composition
20080255084 - Combination of organic compounds
20080255135 - Novel 1-aza-bicycloalkyl derivatives
20080255139 - Use of 4- (4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms
20080255149 - Carboxyamine compounds and methods of use thereof
20080255171 - Combination of nilotinib with farnesyl transferase inhibitors
20080255176 - Quinoline derivatives
20080255356 - Chiral tertiary aminoalkylnaphthols
20080255369 - Synthesis of renin inhibitors involving a cycloaddition reaction
20080249104 - Salt forms of 4- (4-methylpiperazin-1-ylmethyl) -n- [4-methyl-3- (4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl]- benzamide
20080249318 - Process for phenylacetic acid derivatives
20080242659 - Compositions and methods for reducing cardiovascular morbidity and/or mortality
20080242662 - Organic compounds
20080242683 - Organic compounds
20080242686 - Pharmaceutical compositions of lavendustin
September 2008 - Novartis Corporate Intellectual Property patents
20080233182 - Organic compounds
20080234179 - Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
20080234285 - Combination of organic compounds
20080234294 - Cxcr4 binding molecules
20080234490 - Metal salts of 2' - (1h-tetrazol-5yl) -1. 1'-biphenyl-4-carboxaldehyde
20080226731 - Pharmaceutical compositions comprising i matinib and a release retardant
20080226737 - Use of calcitonin for the treatment of ra
20080227125 - Secreted polypeptide species reduced in cardiovascular disorders
20080227755 - Method of administering bisphosphonates
20080227800 - Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome
20080227825 - Formulation
20080227845 - Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
20080227980 - Preparation of a 7h-pyrrolo [2,3-d] pyrimidine derivative
20080216825 - Insulated cansister for metered dose inhalers
20080219977 - Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
20080219996 - Molecular markers associated with bone metastasis
20080221065 - Organic compounds
20080221080 - Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias
20080221126 - Use of hdac inhibitors for the treatment of myeloma
20080221200 - Combination of organic compounds
20080221336 - Pparalpha/gamma agonists and processes of preparing
20080213330 - Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons
20080213385 - Formulations for 7- (t-butoxy) iminomethyl camptothecin
20080214445 - Method of treating a solid tumor disease comprising administering a combination comprising imatinib and an inhibitor of an efflux pump active at the blood brain barrier or demethyl imatinib
20080214521 - Sensitization of drug-resistant lung caners to protein kinase inhibitors
20080214595 - Use of rapamycin derivatives for the treatment and/or prevention of cardiovas cular disorders
20080214596 - Biomarkers for sensitivity of proliferative diseases to mtor inhibitors
20080214662 - Methods for the treatment of dementia based on apo e genotype
August 2008 - Novartis Corporate Intellectual Property patents
20080206237 - Synergistic combination of xolair/omalizumab/e25 with immunosuppressive agent
20080206240 - Antilymphocyte antibody induction
20080206322 - Pharmaceutical multiparticulate composit ion comprising mycophenolic acid or myco phenolate sodium and combination compositions with rapamycin
20080207496 - Organic compound
20080207533 - Pharmaceutical compositions
20080207565 - Use of bisphosphonates for pain treatment
20080207567 - Treatment of hcv disorders
20080207591 - Organic compounds
20080207648 - Organic compounds
20080207686 - Peptide deformylase (pdf) inhibitors 4
20080207692 - Stabilized and preserved ketoifen ophthalmic compositions
20080207739 - Ophthalmic uses of s1p receptor modulators
20080207921 - Organic compounds
20080199428 - Treatment of liver diseases in which iron plays a role in pathogenesis
20080199465 - Immunosuppressive combination and its use in the treatment or prophylaxis of insulin-producing cell graft rejection
20080199855 - Identification and characterization of a subset of glioblastomas sensitive to treatment with imatinib
20080200438 - Treatment of autoimmune diseases
20080200466 - Organic compounds for the treatment of inflammatory or allergic conditions
20080200483 - Purine derivatives for use as adenosin a-2a receptor agonists
20080200486 - Combination of organic compounds
20080200487 - Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
20080200488 - Combinations comprising a protein kinase inhibitor being a pyrimidylaminobenzamide compound and a hsp90 inhibitor such as 17-aag
20080200489 - Combination of organic compounds
20080200510 - Combination of organic compounds
20080200687 - Preparation of terazole derivatives
20080200691 - Process for the synthesis of organic compounds
20080200692 - Process for the synthesis of organic compounds
20080193415 - Hsa-free formulations of interferon-beta
20080193529 - Direct compression formulation and process
20080193558 - Stabilized and preserved ketotifen ophth almic compositions
20080193564 - Method for preventing or reducing secondary fractures after hip fracture
20080193603 - Method and composition for nutritionally improving glucose control and insulin action
20080194470 - Nim811 in cerebral ischemia and brain and spinal cord injury
20080194492 - Plant extracts for the treatment of incresed bone resorption
20080194526 - Liquid formulations
20080194551 - Acetylene derivatives
20080194579 - 1,3-dihydro-imidazo [4,5-c] quinolin-2-ones as lipid kinase inhibitors
20080194595 - Quinazolinone derivatives useful as vanilloid antagonists
20080194613 - P53 wild-type as biomarker for the treatment with mtor inhibitors in combination with a cytotoxic agent
20080194614 - Combination of organic compounds
20080194629 - 3-mono-and 3,5-disubstituted piperidine derivatives as renin inhibitors
20080196114 - Rgmc modified transgenic animals
20080187510 - Methods for improving drug disposition
20080187582 - Pharmaceutical composition comprising an indolylmaleimide derivative
20080188451 - Inhibitors of tyrosine kinases
20080188504 - Process for preparing pure amorphous rosuvastatin calcuim
20080188515 - Imidazo [1,2-a] pyridine derivatives useful as peptide deformylase (pdf) inhibitors
20080188656 - Process for the synthesis of 5- (methyl-1h-imidazol-1-yl) -3- (trifluoromethyl) -benzeneamine
July 2008 - Novartis Corporate Intellectual Property patents
20080181854 - Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides
20080183010 - Method for asymmetric alkynylation of al pha-imino esters
20080176849 - Deacetylase inhibitors
20080176879 - Pyrimidylaminobenzamide derivatives for sytemic mastocytosis
20080176916 - A-amino-n-hydroxy-acetamide derivatives
20080171017 - Use of cd25 antibodies in immunotherapy
20080171086 - Solid dosage forms of valsartan and amlo dipine and method of making the same
20080171350 - Neural cell differentiation method from es cells
20080167367 - Stable hydrate of a muscarinic receptor antagonist
20080161307 - Organic compounds
20080161321 - Use of renin inhibitors in therapy
20080161329 - Pharmaceutical uses
20080161334 - Macrolides
20080161369 - Epothilone derivative for the treatment of hepatoma and other cancer diseases
20080161410 - Aminoalkanol derivatives
20080161544 - Chromatographic separation of therapeutic polypeptides
20080161558 - N-formyl hydroxylamines
June 2008 - Novartis Corporate Intellectual Property patents
20080152644 - Genes involved in neurodegenerative conditions
20080153836 - 1h-quinazoline-2,4-diones
20080145410 - Manufacture process
20080146578 - Indolylmaleimide derivatives
20080146647 - Acetylene derivatives having mglur 5 antagonistic activity
20080146662 - Methods and compositions for treatment of cancer pain
20080146671 - Microemulsion preconcentrate comprising a renin inhibitor
20080138316 - Use of a combination of cyclosporine and pegylated interferon for treating hepatitis c (hcv)
20080138429 - Coated particles and pharmaceutical dosage forms
20080139449 - X-ray structure of human fpps and use for selecting fpps binding compounds
20080139480 - Combination of (a) n--4-(3- pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the usethereof
20080139587 - Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof
20080139662 - Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases
20080131475 - Methods of use of dual ppar agonist compounds and drug delivery devices containing such compounds
20080131884 - Tubulin mutation diagnostic
20080132504 - 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
20080132518 - Organic compounds
20080132534 - Pharmaceutical composition comprising a macrolide immunomodulator
May 2008 - Novartis Corporate Intellectual Property patents
20080125450 - Pharmaceutical compositions comprising a camptothecin derivate
20080118564 - Pharmaceutical composition containing candesartan cilexetil as lipophilic crystalline substance
20080118951 - Nogo receptor homologues and their use
20080119411 - Orally administering parathyroid hormone and calcitonin
20080119529 - Combinations comprising epothilones and pharmaceutical uses thereof
20080119557 - Combination of organic compounds
20080114001 - Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity
20080114056 - Chromone derivatives useful as vanilloid antagonists
20080107613 - Pharmaceutical composition comprising a macrolide t-cell immunomodulator and anti-photoaging agent
20080108628 - Indolylmaleimide derivatives
20080108703 - Methods for improving bioavailability of a renin inhibitor
April 2008 - Novartis Corporate Intellectual Property patents
20080096864 - Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
20080096865 - Method for treating neovascularization
20080096943 - Organic compunds
20080096972 - Compound formulations of 2-amino-1, 3-propanediol compounds
20080096978 - Ophthalmic solutions
20080090270 - Nogo receptor homologues and their use
20080090878 - Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
20080085902 - Combination of a vegf receptor inhibitor or with a chemotherapeutic agent
20080085914 - Use of organic compounds
20080081841 - Materials and methods for modulating cell motility
20080081927 - Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine
March 2008 - Novartis Corporate Intellectual Property patents
20080075773 - New oral formulation
20080076793 - Use of an ascomycin for the treatment of blepharitis
20080076811 - Combinations comprising depeptidypeptidase-iv inhibitors and antidiabetic agents
20080070852 - Method for the extraction of pharmaceutically active products from spermatophyte plants, products thus obtained and their use in the medical field, in particular as substances with immunomodulating activity
20080070885 - Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof
20080070897 - Spontaneously dispersible n-benzoyl staurosporine compositions
20080070922 - Combination of organic compounds
20080071082 - Heteroatoms-containing tricyclic compounds
20080064027 - Tel/etv6-mediated inhibition of cell proliferation
20080064760 - Spontaneously dispersible pharmaceutical composition
February 2008 - Novartis Corporate Intellectual Property patents
20080050443 - Fast release composition including melt granules of a moisture sensitive drug and process for manufacturing thereof
20080044371 - Taste-masked composition of cationic exchange resin
20080045530 - Organic compounds and their uses
20080045757 - Chiral tertiary aminoalkylnaphthols
20080038277 - Dna pkinase inhibitors for treating cancer and diabetes
20080038341 - Direct compression formulation and process
20080038768 - Assay for ubiquitin mediated proteolysis
20080039440 - Cyclic diaryl ureas suitable as tyrosine kinase inhibitors
20080033207 - Preparation of r-5- (2-(2-ethoxyphenoxyetylamino) -2-methoxybenzen-sulphonamide hydrochloride of high chemical
January 2008 - Novartis Corporate Intellectual Property patents
20080026981 - Pharmaceutical compositions
20080027032 - Combinations comprising cox-2 inhibitors and aspirin
20080027106 - Methods of treating psychosis and schizphrenia based on polymorphisms in the cntf gene
20080019863 - Package for a pharmaceutical product
20080021200 - Processes for preparing a polypeptide
20080021225 - Process for the synthesis of peptides containing a 4-hydroxy-proline substructure
20080014269 - Oxacarbazepine film-coated tablets
20080015261 - Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
20080008765 - Taste-masking pharmaceutical compositions
20080009470 - Acremonic acid derivatives
20080003212 - Atp diphosphohydrolase (cd39) gene therapy for inflammatory or thrombotic conditions for transplantation and means therefor
20080003267 - Pharmaceutical composition
20080004231 - Disease-associated protein
20080004296 - Organic compounds
December 2007 - Novartis Corporate Intellectual Property patents
20070295332 - Inhaler device
20070298022 - Identification of phospholipase a2 as target in cancer treatment, with special emphasis on colorectal cancer and its mechanism of action
20070298058 - Pharmaceutical compositions comprising ascomycin
20070298096 - Analgesic/antipyretic compositions for enhanced absorption
20070298108 - Pharmaceutical formulation
20070299024 - Cloning and characterization of 5'flanking regions of a human aggrecanase-1 gene
20070299047 - Combination of organic compounds
20070299049 - Pharmaceutical uses of staurosporine derivatives
20070289889 - Biomarkers for the prediction of drug-in duced diarrhea
20070292515 - Solid dosage form containing a taste masked active agent
20070293473 - Use of acylaminoalkenylene-amide derivatives in functional motility disorders of the viscera
20070293474 - Combination of a dpp iv inhibitor and a cardiovascular compound
20070293504 - N-phenyl-2-pyrimidine-amine derivatives
20070293672 - N-phenyl-2-pyrimidine-amine derivatives
20070293673 - N-phenyl-2-pyrimidine-amine derivatives
20070293678 - Process for the preparation of 6, 8-subs tituted '1, 7 naphthpyridin derivatives by reacting the 8-halo-'1, 7 naphthpyrid in-derivate with an organic boronic acid derivatives and intermadiates of this process
20070293683 - N-phenyl-2-pyrimidine-amine derivatives
20070286842 - Organic compounds and their uses
20070287722 - Drop preparations comprising dimetindene
20070287970 - Method for systemic drug delivery through the nail
20070278124 - Casing for a blister package
20070281956 - Phenylpyrimidine amines as ige inhibitors
20070282013 - Pharmaceutical compositions comprising peranhydrocyclodextrin
November 2007 - Novartis Corporate Intellectual Property patents
20070275382 - Biomarkers for the efficacy of somatostatin analogue treatment
20070275391 - Novel g-protein coupled receptors and dna sequences thereof
20070275884 - Use of modified cyclosporins for the treatment of hcv disorders
20070275928 - Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
20070275969 - Nanoparticles for oral administration of pharmaceutical agents of low solubility
20070275996 - Use of statins for the treatment of metabolic syndrome
20070276004 - Pharmaceutical composition comprising an immunosuppressant for use in the treatment of skin diseases
20070276012 - Process for preparing thiazolidinediones
20070270499 - Use for 2-amino-2-propane-1, 3-diols
20070264252 - Modulators of ms4a gene products
20070264333 - Method of treatment
20070265274 - 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases
20070265279 - Use of mglur5 antagonists for the treatment of pruritic conditions
20070265281 - Organic compounds and their uses
20070265285 - Quinazolinone derivatives and their use as cb agonists
20070265292 - N-phenyl-2-pyrimidine-amine derivatives
20070265297 - Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions
20070265328 - Certain substituted spirocyclic lactams and use thereof as pharmaceuticals
20070258972 - Combination of a histone deacetylase inhibitor with a death receptor ligand
20070259835 - Phosphinic acid derivatives
20070259848 - Azetidine derivatives as ccr-e receptor
20070254944 - Use of organic compounds
October 2007 - Novartis Corporate Intellectual Property patents
20070248955 - Use of genetic polymorphisms to predict drug-induced hepatotoxicity
20070249586 - Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity
20070249617 - Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists
20070249639 - Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives
20070249657 - 1-aza-bicyclo3.3.1nonanes
20070249827 - Meropenem intermediatein in crystalling form
20070238124 - Differentially expressed genes related to coronary artery disease
20070238135 - Novel g-protein coupled receptor and dna sequences thereof
20070231382 - Pharmaceutical composition
20070232524 - Oral administration of calcitonin
20070232606 - Compounds and compositions as cathepsin s inhibitors
20070232658 - Protein kinase c inhibitors for the treatment of autoimmune diseases and of transplant rejiction
September 2007 - Novartis Corporate Intellectual Property patents
20070225222 - Use of heparin-binding domain of fibronectin for diagnosis and treatment of cancer
20070225260 - Amino-propanol derivatives
20070225286 - Compounds and compositions as protein kinase inhibitors
20070225335 - Pyrazole derivatives for treating condit ions mediated by activation of the adeno sine a2b or a3 receptor
20070225337 - Novel co-precipitate of amorphous rosiglitazone
20070225497 - Chiral tertiary aminoalkylnaphthols
20070218134 - Compositions comprising organic compounds
20070218513 - Differentially expressed genes related to coronary artery disease
20070219115 - Pharmaceutical uses of bisphosphonates
20070219143 - Antiinflammatory lactones
20070219189 - Mif-inhibitors
20070212418 - Microparticles comprising somatostatin analogues
20070213317 - Inhibitors of the mutant form of kit
20070213355 - 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases
20070207519 - Cephalosporin c acylase mutant and method for preparing 7-aca using same
20070208018 - Quinazoline derivatives
20070208055 - Alternative synthesis of renin inhibitors and intermediates thereof
20070208071 - Oxidative degradation products of atorvastatin calcium
20070208075 - Pharmaceutical compositions
August 2007 - Novartis Corporate Intellectual Property patents
20070202057 - Disintegrable oral films
20070203084 - Interfering rna duplex having blunt-ends and 3'-modifications
20070196270 - Compounds as ccri antagonists
20070196286 - Aerosol composition comprising formoterol
20070196488 - Oral matrix formulations comprising licarbazepine
20070196890 - Prebiotic effect analysis
20070197560 - Cgmp pde 5 inhibitors for inhalation in the treatment of sexual dysfunction
20070197582 - Imidazo[[1, 5-a] pyridine derivatives and methods for treating aldosterone mediated diseases
20070197611 - Fermentative preparation process for and crystal forms of cytostatics
20070197655 - Galenic formulations of organic compounds
20070190143 - Disintegrating tablets comprising licarb azepine
20070191259 - Inhibition of s6 kinaze activity for the treatment of insulin resistance
20070191338 - Combinations comprising staurosporines
20070191401 - Indolylmaleimide derivatives
20070191487 - Galenic formulations of organic compounds
20070191601 - Process for production of intermediates for use in cefalosporin synthesis
20070184019 - Pharmaceutical composition comprising an active principal and sulphobetaine
20070184061 - Indolylmaleimide derivatives
20070184464 - Rna probes
20070185172 - Organic compounds
20070178520 - Screening assay for modulators of interaction between interleukin-12 and/or -23 with their receptors
20070179298 - Chemical process for the preparation of intermediates to obtain n-formyl hydroxy-lamine compounds
20070179308 - Process for preparing amophous (4r-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-4-fluorophenyl)-5-(1-methylethyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]-dioxane-4-yl-acetic acid
July 2007 - Novartis Corporate Intellectual Property patents
20070172421 - Substituted pyrrolidine-2-ones
20070173472 - Methods and reagents for the treatment of apoptosis-related disorders
20070173496 - Novel polymorph e of olanzapine and preparation of anhydrous non-solvated crystalline polymorphic form i of 2-methyl-4(4-methyl-1-piperazinyl)-10h-thieno[2,3-b][1,5] benzodiazepine (olanzapine form i) from the polymorphic olanzapine form e
20070173637 - Process for the preparation of perindopril using tetramethyluronium salts as coupling reagents
20070166363 - Use of cholinesterase inhibitors for treating vascular depression
20070167449 - Thiazole and pyrazole derivatives as flt-3 kinase inhibitors
20070167478 - Biomarkers for sensitivity of proliferative diseases to mtor inhibitors
20070160528 - Method to evaluate the likelehood of development of bone metastasis based on the determination of calcium binding proteins
20070160673 - Amoxicilline instant granulate
20070161523 - Lens care compositions
20070161603 - Method of administering bisphosphonates
20070161618 - Isothiourea derivatives
20070161632 - 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
20070161709 - Amorphous tamsulosin hydrochloride
20070154520 - Pharmaceutical compositions
20070154550 - Pharmaceutical composition comprising anticonvulsant with taste mask coating
20070155721 - Chemokine receptor antagonists
20070155757 - Use of pyrimidine compounds in the preparation of parasiticides
20070155759 - Pharmaceutical uses
20070155772 - Use of genetic polymorphisms that associate with efficacy of treatment of inflammatory disease
20070155817 - Indolylmaleimide derivatives
20070155970 - Process for the manufacture of hmg-coa reductase inhibitory mevalonic acid derivatives
20070155989 - Synthesis of optically pure(r)-5-(2-amynopropyl)-2-methoxybenzenesulphonamide
June 2007 - Novartis Corporate Intellectual Property patents
20070146698 - Floating cuvette for lens inspection
20070148186 - Simarouba amara and/or momordica charantia extracts for the treatment of coccidiosis in poultry
20070148247 - Pharmaceutical composition which reduces or eliminates drug abuse potential
20070149451 - Combination of a dpp iv inhibitor and an antiobesity or appetite regulating agent
20070149504 - Use of neurokinin antagonists in the treatment of urinary incontinence
20070149539 - Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
20070149573 - S-omeprazole magnesium
20070149587 - Valsartan salts
20070141089 - Topical composition comprising terbinaf ine adn hydrocortisone
20070141149 - Controlled-release pharmaceutical formulation
20070141618 - Genes expressed in breast cancer as prognostic and therapeutic targets
20070142266 - Combination comprising a p-gp inhibitor and an anti-epileptic drug
20070142273 - Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis
20070142401 - Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation
20070142405 - Bicyclic heterocyclic p-38 kinase inhibitors
20070142407 - Benzo (1,2,5) thiadiazole als crf-antagonisten
20070142428 - Isoquinoline-3-carboxylic acid amides and pharmaceutical uses thereof
20070142475 - Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides and use as renin inhibitors
20070134319 - Pharmaceutical formulations of bisphosphonates
20070134344 - Antibiotic compositions
20070134744 - Epothilone resistant cell lines
20070135353 - Crystalline n-formyl hydroxylamine compounds
20070135444 - Treatment of neuroblastoma
20070135448 - Use of cathepsin k inhibitors for treating of severe bone loss diseases
20070135460 - 7h-pyrrolopyrimidine derivatives
20070135498 - Organic compounds
20070135501 - Amino acid derivatives
20070135502 - Heterocyclic compounds and methods of use
20070128263 - Transdermal therapeutic system
20070128268 - Pharmaceutical compositions comprising an antibiotic
20070128277 - Coated tablets
20070128664 - Secreted polypeptide species associated with cardiovascular disorders
20070129366 - Methods for the treatment of chronic pain and compositions therefor
20070129389 - Use of pyridinyl-pyrimidinylamino-benzamide derivatives for the treatment of amyloid related disorders
20070129411 - Treatment of proliferative diseases with epothilone derivatives and radiation
20070129413 - Coupling reactions useful in the preparation of (1h-tetrazol-5-yl) biphenyl derivatives
May 2007 - Novartis Corporate Intellectual Property patents
20070122475 - Taste masking composition
20070122485 - Organic compounds
20070123498 - Combination of organic compounds
20070123580 - Combination of histone deacetylase inhibitors with chemotherapeutic agents
20070123593 - Pharmaceutical composition comprising 5-methyl-2(2'-chloro-6'-fluoroanilino)phenylacetic acid
20070116784 - Imatinib combinations for head and neck cancers
20070117764 - Compositions comprising macrolide t-cell immunomodulators or immunosuppressants in combination with antibacterials
20070117833 - Pharmaceutical compositions
20070111210 - Biomarkers for graft rejection
20070111991 - Novel dibenzo [b, f] oxepine-10-carboxamides and pharmaceutical uses thereof
20070111999 - P-38 kinase inhibitors
20070112056 - Stable modifications of tegaserod hydrogen maleate
20070104846 - Aseptic pudding with puree
20070105101 - Gene expression associated with osteobla st differentiation
20070105147 - Rapid method for screening compounds for in vivo activity
20070105169 - Secreted polypeptide species associated with cardiovascular disorders
20070105830 - Processes for the preparations of cefepime
20070105839 - 2, 4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
20070105894 - Combination of at least two compounds selected from an at1-receptorantagonist or an ace inhibitor or a hmg-co-a reductase inhibitor
20070098635 - Secreted polypeptide species associatedwith cardiovascular disorders
20070099250 - Methods for treating proliferative diseases and for monitoring the effectiveness of treatment of proliferative diseases
20070099828 - Biomarkers for the efficacy of calcitonin and parathyroid hormone treatment
April 2007 - Novartis Corporate Intellectual Property patents
20070092527 - Proton-sensing g-protein coupled receptors and dna sequences thereof
20070092582 - Methods of preserving ophthalmic solutions and preserved ophthalmic solutions
20070093412 - Pharmaceutical composition comprising cyclic somatostatin analogues
20070093431 - Combination of organic compounds
20070093506 - Inhibitors of tyrosine kinases
20070093507 - Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives
20070087051 - Pharmaceutical composition
20070088084 - Malic acid addition salts of terbinafine
20070081971 - Stable pharmaceutical compostion comprising granulocyte-colony stimulating factor
20070082016 - Microemulsion preconcentrate comprising a renin inhibitor
20070082339 - Methods and compositions for screening for hdac inhibitory activity
20070082363 - Secreted polypeptide species reduced cardiovascular disorders
20070082873 - Combinations comprising ampa receptor antagonists for the treatment of schizophrenia
20070082914 - 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating pulmonary fibrosis
20070082945 - Discodermolide compositions
20070078142 - Treatment of tuberous sclerosis associated neoplasms
20070078164 - 4-phenylpiperidine derivatives as renin inhibitors
20070078258 - Purification process
March 2007 - Novartis Corporate Intellectual Property patents
20070045148 - Containment for supplying individual pouches
20070045354 - Contact lens care product
20070048379 - Valproate tablet
20070048388 - Stabilized and preserved ketotifen ophthalmic compositions
20070048389 - Stabilized and preserved ketotifen ophthalmic compositions
20070049616 - Organic compounds
February 2007 - Novartis Corporate Intellectual Property patents
20070041988 - Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines
20070042457 - Process for producing penicillin
20070042943 - Novel cyclosporin galenic forms
20070042948 - Vav inhibition in graft rejection
20070042994 - Pharmaceutical compositions comprising peranhydrocyclodextrin
20070043013 - 1,3 disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases
20070043020 - Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
20070043029 - 11-phenyl-dibenzodiazepine derivatives as rxr-antagonists
20070043048 - 2-aminopyrimidine derivatives and their medical use
20070043098 - Process for the preparation of tetrazole derivatives from organo boron and organo aluminium azides
20070043102 - Oral suspension of tegaserod
20070043214 - Derivatives of azithromycin
20070036810 - Cyclic amp response element activator proteins and uses related thereto
20070036852 - Rapidly dispersing/disintegrating compositions
20070036857 - Pharmaceutical multiparticulate composition comprising mycophenolic acid or mycophenolate sodium and combination with rapamycin
20070036863 - Oxacarbazepine film-coated tablets
20070037792 - Pharmaceutical compositions
20070037825 - Enhancing the effect of radioimmunotherapy in the treatment of tumors
20070037826 - Indolylmaleimide derivatives
20070037835 - Pharmaceutical composition comprising a cathepsin s inhibitor and an opioid
20070037881 - Amidoacetonitrile derivatives
20070031336 - 3h-phenoxazine derivatives suitable as near-infrared imaging agents, preparation an use thereof
20070031493 - Pharmaceutical compositions
20070032483 - Process for the production of mycophenolate mofetil
20070032487 - Inhibitors of phosphatidylinositol 3-kinase
20070032507 - Indolylmaleimide derivatives
20070032538 - Use of compounds
20070032869 - Method and apparatus for applying a coating to an ophthalmic lens
20070023942 - Method of creating ophthalmic lenses using modulated energy
20070026017 - Brachyspira pilosicoli 72kda outer-membrane protein and diagnostic and therapeutic uses thereof
20070026512 - Atomic structure of the catalytic domain for use in designing and identifying inhibitors of zap-70 kinase
20070027048 - Lens care product containing dexpanthenol
20070027167 - Use of c-src inhibitors alone or in combinaton with sti571 for the treatment of leukaemia
20070027197 - Pharmaceutical composition and method for the treatment of diseases using hmg-coa reductase inhibitors and insulin secretion enhancers or sensitizers
January 2007 - Novartis Corporate Intellectual Property patents
20070020673 - Model of autoimmune disease and methods for identifying agents against autoimmune disease
20070020723 - Ceramide kinase-like proteins
20070021377 - Pharmaceutical composition comprising a macrolide immunomodulator
20070021432 - Treatment of mesothelioma
20070022483 - Transgenic animal model for alzheimer's disease
20070014818 - Liquid formulations with high concentration of human growth hormone (hgh) comprising 1,2-propylene glycol
20070015736 - Pharmaceutical products comprising bisphosphonates
20070015781 - Certain substituted spirocyclic lactams and use thereof as pharmaceuticals
20070009955 - Secreted polypeptide species associated with cardiovascular disorders
20070010494 - Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator
20070010508 - Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
20070004704 - Organic compounds
20070004746 - Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processed for its manufacture and its use
20070004756 - Pharmaceutical compositions
December 2006 - Novartis Corporate Intellectual Property patents
20060293282 - Substituted aminoalkanephosphonic acids
20060293340 - 2-aminopyrimidine derivatives as raf kinase inhibitors
20060287276 - Compositions comprising oligosaccharides
20060287339 - Aza- and polyazanthranyl amides and their use as medicaments
20060287362 - Organic compounds
20060287538 - Process for the preparation of amorphous calcium salt of atorvastatin
20060281091 - Genes regulated in ovarian cancer a s prognostic and therapeutic targets
20060281671 - Organic compounds
20060281714 - Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss
20060281731 - Substituted lactams and their use as anti-cancer agents
20060281790 - Combination
20060275357 - Organic compounds
20060275362 - Rapidly-dissolving pharmaceutical composition for inhibiting ovulation
November 2006 - Novartis Corporate Intellectual Property patents
20060269608 - Pharmaceutical formulation
20060269990 - Process for the preparation of recombinant polypeptides
20060270658 - Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
20060270665 - Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
20060270719 - Alpha-amino-n-hydroxy-acetamide derivatives
20060270730 - Histone deacetylase inhibitors as immunosuppressants
20060263392 - Method for treating neovascularization
20060263424 - Pharmaceutical compositions comprising clavulanic acid
20060264403 - Aminopropanol derivatives
20060264443 - Treatment of rheumatoid arthritis
20060264642 - Mixtures of ionic liquids with lewis acids
20060264653 - Aminoacetonitrile derivatives and their use for controlling parasites
20060257367 - Tumour-cell specific gene expression and its use in cancer therapy
20060257425 - Inactivated nodavirus vaccine
20060258690 - Spiro-substituted pyrrologyrimidines
20060258838 - Preparation of somatostatin peptides
20060251660 - Antibodies to human il-1beta
20060252041 - Pcr-based diagnostic method of detecting a mutation in the b-raf gene
20060252102 - Assays for c-mannosyltransferases
20060252763 - Treatment of von hippel lindau disease
20060252794 - Process for preparing 5-'(r)-2-(5,6-diethyl-indian-2-ylamino)-1-hydroxy-ethyl!-8-hydroxy-(1h)-quinolin-2-one salt, useful as an andrenoceptor agonist
20060246101 - Oral controlled release formulations
20060246439 - Methods to predict cholesterol elevations during immunosuppressant therapy
20060247241 - 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
20060247251 - 2-cyanopyrrolopyrimidines and pharmaceutical uses thereof
20060247255 - Method for preparing a stable gatifloxacin composition
20060247262 - 2,4 di (hetero) -arylamino-pyrimidine derivatives as zap-70 and/or syk inhibitors
20060247268 - N-sulfonylaminothiazole
October 2006 - Novartis Corporate Intellectual Property patents
20060240000 - Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound
20060233818 - Organic compounds
20060233876 - Compositions and methods for reducing cardiovascular morbidity and/or mortality
20060234985 - Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor
20060235059 - Cancer treatment with epothilones
20060228781 - Synthetic gene coding for human granulocyte-colony stimulating factor for the expression in e.coli
20060228783 - Expression vectors, transformed host cells and fermentation process for the production of recombinant polypeptides
20060229290 - Staurosporine derivatives for hypereosinophilic syndrome
20060229345 - Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
20060229445 - Organic compounds
20060229472 - Process for preparing polymorphic form ii of sertraline hydrochloride
20060222684 - Palatable ductile chewable veterinary composition
20060223745 - Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof
20060223756 - Endothelial cell specifically binding peptides
20060223789 - Antibacterial substituted 7-acylamino-3-(methylhydrazono) methyl-cephalosporins and intermediates
20060223818 - N-phenyl-2-pyrimidine-amine derivatives
20060223867 - Cancer treatment with epothilones
September 2006 - Novartis Corporate Intellectual Property patents
20060207721 - Polymer adhesive splicing of water-soluble, orally ingestible thin film webs
20060207912 - Package for a pharmaceutical product and method of manufacturing and sterilizing the package
20060210627 - Direct compression formulation and process
20060210631 - Multi-particulate, modified-release composition
20060211335 - Electric breast pump
20060211656 - Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
20060211658 - Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator
20060211674 - Combination comprising a vasculostatic compound and an alkylating agent for the treatment of a tumor
20060211747 - Methods of screening for compounds which inhibit the activity of cdc34 in a zinc-mediated manner and compounds obtained by this method
20060205673 - 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives
20060205746 - Pharmaceutical compositions
20060205772 - Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type i
20060205795 - Cancer treatment with epothilones
20060199854 - Process for the preparation of n-substituted 2-cyanopyrrolidines
###
This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Novartis Corporate Intellectual Property in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Novartis Corporate Intellectual Property with additional patents listed. Browse our Agent directory for other possible listings.
###
FreshPatents.com Support
|
REGISTER now for FREE 
